Adalimumab for the treatment of psoriasis.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 2, Issue , 2009, Pages 49-54

  Turner, D ^a   Picot, J ^b   Cooper, K ^b   Loveman, E ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; PSORIASIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; HUMANS; PSORIASIS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84886943020     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl2/07     Document Type: Review

References (4)